Evidence map›Paper›PMID 26082617›Full record

ArticleDrug design, development and therapy2015

Protective effect of Huang Gan formula in 5/6 nephrectomized rats by depressing the Wnt/β-catenin signaling pathway.

Liqian Mo, Xiaoyan Xiao, Shaolian Song, Hui Miao, Shiting Liu, Dan Guo, Xiao Li, Can Bu, Lianbing Hou, Xixiao Yang

Open access · goldAbstract readComparative Study
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Liqian MoDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Xiaoyan XiaoDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Shaolian SongDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Hui MiaoSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Qingdao, People's Republic of China.
Shiting LiuDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Dan GuoDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Xiao LiDepartment of Pharmacy, The Affiliated Hospital of Qingdao University Medical School, Qingdao, People's Republic of China.
Can BuDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Lianbing HouDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Xixiao YangDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Qingdao, People's Republic of China.
Southern Medical University · CNQingdao University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huang Gan formula (HGF) is a new traditional Chinese herbal medicine created according to the basic theory of traditional Chinese medicine. The aim of this study is to evaluate the effects of HGF on chronic kidney disease and determine the mechanisms of action. The extract of HGF was prepared, and qualitative and quantitative determination of phytochemical was performed with quadrupole time-of-flight mass spectrometer and high-performance liquid chromatography. Sprague-Dawley rats (n=72) were submitted to 5/6 nephrectomy (Nx), and then respectively treated with uremic clearance granule, losartan, HGF low dose, HGF middle dose, and HGF high dose once per day for 12 weeks. The sham group of operated rats (n=22) was treated with normal saline or HGF middle dose as a background control group. Blood and urine biochemical parameters, renal tissue morphology, and mRNA and proteins of Wnt/β-catenin signaling pathways were investigated. The results showed that the quality of the extraction process could be controlled, and a total of eight major compounds were identified and quantified. HGF could decrease the level of serum creatinine, blood urea nitrogen, and urine protein and increase the renal index and creatinine clearance rate in a dose-dependent manner. HGF also remarkably reduced the glomerulosclerosis and tubulointerstitial fibrosis by blocking the Wnt/β-catenin signaling pathway through inhibiting the Wnt1, β-catenin, transcription factor 4, and fibronectin 1 expressions, simultaneously measured through mRNA and protein levels in the remnant kidney. These results suggest that extraction of HGF could improve remnant renal function and possibly ameliorate glomerulosclerosis and tubulointerstitial fibrosis by depressing the Wnt/β-catenin signaling pathway.

Indexed as

AnimalsDisease Models, AnimalDose-Response Relationship, DrugDrugs, Chinese HerbalKidney Function TestsLosartanMaleNephrectomyRatsRats, Sprague-DawleyRenal Insufficiency, ChronicRNA, MessengerWnt Signaling PathwayDrugs, Chinese HerbalLosartanRNA, Messengerchronic kidney diseaseHuang Gan formulatraditional Chinese medicineWnt/β-catenin signaling pathway

Identifiers

PMID26082617
PMCPMC4461094
OpenAlexW1656194346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.